'Bender et al. report that a phase 2 randomized trial of a single dose of expanded Tregs showed no efficacy in preserving C-peptide, an indicator of β cell function, in early-onset T1D. This negative in vivo result comes despite the suppressive capacity of the expanded Tregs in vitro, and will inform future studies of the role of polyclonal Tregs in T1D.'
#Immunology #Immunotherapy #Treg #Diabetes
https://www.science.org/doi/full/10.1126/scitranslmed.adn2404